NCT01022359

Brief Summary

This study aims to compare two available types of central venous haemodialysis catheters (lines) - CVCs, and will examine how easy they are to insert, complications, blood flow on dialysis over time, line loss, line clotting and infective events. It will examine whether the LifeCath type of CVC can deliver high blood flow rates from first use after insertion and equivalent function and complication rate to the Tesio type of CVC that is in use in our centre already. Complications relating to dialysis access make up 30% of admissions for haemodialysis patients and so this is a study that could benefit patients and their care providers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2008

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

November 30, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 1, 2009

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2010

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2011

Completed
9.6 years until next milestone

Results Posted

Study results publicly available

April 22, 2021

Completed
Last Updated

April 22, 2021

Status Verified

March 1, 2021

Enrollment Period

1.7 years

First QC Date

November 30, 2009

Results QC Date

March 2, 2021

Last Update Submit

March 26, 2021

Conditions

Keywords

haemodialysisvascular accesscentral venous catheter

Outcome Measures

Primary Outcomes (1)

  • Blood Flow Rate at First Use After Insertion

    First haemodialysis session after insertion

Secondary Outcomes (6)

  • Achievement of Flow Rates>=450ml/Min at Dialysis Session

    flow rate measured at each session; session at 12 months reported

  • Line Retention (Either/Both Lumens)

    12 months

  • Infective Episodes (Catheter & Non-catheter Related)

    12 months

  • Catheter Dysfunction Requiring Use of Thrombolytic Agents

    12 months

  • Complications at Catheter Insertion

    Day 1

  • +1 more secondary outcomes

Study Arms (2)

Tesio Catheter

ACTIVE COMPARATOR

Patients randomised to receive the established catheter type in use at our centre \[control\]

Device: TesioCath

LifeCath

ACTIVE COMPARATOR

Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)

Device: LifeCath Twin

Interventions

TesioCathDEVICE

Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access

Also known as: BioFlex TesioCath (TM) - MedComp, Harleysville, PA, USA
Tesio Catheter

Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access

Also known as: Vygon LifeCath Twin - Vygon(UK) Ltd, Cirencester, Gloucs, UK
LifeCath

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>=18 years old
  • No history of prior central venous catheter insertion
  • Medically fit for procedure (able to lie flat, no haemodynamic instability)
  • No active infection (recent positive blood cultures, clinical signs of infection, CRP\>100)
  • Able to give informed consent
  • Expected to survive more than 12 months after catheter insertion

You may not qualify if:

  • As above

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Imperial College Healthcare NHS Trust

London, W12 0HS, United Kingdom

Location

Related Publications (4)

  • Duncan ND, Singh S, Cairns TD, Clark M, El-Tayar A, Griffith M, Hakim N, Hamady M, McLean AG, Papalois V, Palmer A, Taube D. Tesio-Caths provide effective and safe long-term vascular access. Nephrol Dial Transplant. 2004 Nov;19(11):2816-22. doi: 10.1093/ndt/gfh467. Epub 2004 Aug 31.

    PMID: 15340094BACKGROUND
  • Perini S, LaBerge JM, Pearl JM, Santiestiban HL, Ives HE, Omachi RS, Graber M, Wilson MW, Marder SR, Don BR, Kerlan RK Jr, Gordon RL. Tesio catheter: radiologically guided placement, mechanical performance, and adequacy of delivered dialysis. Radiology. 2000 Apr;215(1):129-37. doi: 10.1148/radiology.215.1.r00mr43129.

    PMID: 10751478BACKGROUND
  • Hassell DD 3rd, Vesely TM, Pilgram TK, Audrain JL. Initial performance of Tesio hemodialysis catheters. J Vasc Interv Radiol. 1999 May;10(5):553-8. doi: 10.1016/s1051-0443(99)70082-5.

    PMID: 10357479BACKGROUND
  • Power A, Hill P, Singh SK, Ashby D, Taube D, Duncan N. Comparison of Tesio and LifeCath twin permanent hemodialysis catheters: the VyTes randomized trial. J Vasc Access. 2014 Mar-Apr;15(2):108-15. doi: 10.5301/jva.5000202. Epub 2014 Feb 5.

Results Point of Contact

Title
Neill Duncan
Organization
Imperial College London

Study Officials

  • Neill Duncan, MBBS MRCP

    Imperial College Healthcare NHS Trust

    PRINCIPAL INVESTIGATOR
  • Albert Power, MBBChir MRCP

    Imperial College Healthcare NHS Trust

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 30, 2009

First Posted

December 1, 2009

Study Start

October 1, 2008

Primary Completion

July 1, 2010

Study Completion

September 1, 2011

Last Updated

April 22, 2021

Results First Posted

April 22, 2021

Record last verified: 2021-03

Locations